Trospium Chloride Tablet, Film Coated
Product Images NDC 76282-336

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Trospium Chloride (NDC 76282-336). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Exelan Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure-1 (Figure 1)

Pharmacokinetic curve showing plasma concentration (ng/mL) of Trospium Chloride over time in hours post-dose, up to 48 hours. The graph depicts plasma levels peaking early within the first 4 to 6 hours and then gradually declining to near zero by 48 hours. Error bars indicate variability at each time point.*

FDA Label Image

Structure (Trospium 01)

Chemical structure diagram of Trospium Chloride depicting its molecular framework including rings and functional groups as shown in the image.*

FDA Label Image

Trospium-chloride-20mg (Trospium Chloride 20mg)

Label for Trospium Chloride Tablets, USP, 20 mg by Exelan Pharmaceuticals Inc. The film-coated tablets come in a bottle containing 60 tablets. The label includes storage instructions, manufacturer and labeler details, a barcode, and indicates the product is for prescription use only.*

FDA Label Image

Figure2 (Trospium Fig2)

A line graph titled 'Mean Change from Baseline in Urinary Frequency/24 Hours, by Visit: Study 1' showing mean (± SE) change in urinary frequency over 12 weeks. Two groups are compared: Placebo (N=256) with a dashed line and open circles, and Trospium Chloride (N=253) with a solid line and filled circles. Trospium Chloride shows a greater reduction in urinary frequency from baseline at weeks 4 and 12 than placebo.*

FDA Label Image

Figure3 (Trospium Fig3)

A line graph titled 'Mean Change from Baseline in Urge Incontinence/Week, by Visit: Study 1' comparing placebo (N=256) and Trospium Chloride (N=253) over 12 weeks of treatment. The Y-axis shows mean change with standard error, and the X-axis shows weeks of treatment. Both lines show decreases in urge incontinence, with Trospium Chloride demonstrating greater reductions at weeks 4 and 12, supported by p-values of 0.003 and 0.012 respectively.*

FDA Label Image

Fig4 (Trospium Fig4)

A line graph titled 'Mean Change from Baseline in Urinary Frequency/24 Hours, by Visit: Study 2,' comparing two groups, PLACEBO and SANCTURA®. The x-axis represents weeks of treatment (1, 4, 12). The y-axis shows mean change (± SE) with values ranging from 0 to -0.3. Data points indicate a greater decrease in urinary frequency with SANCTURA® over time compared to placebo, with p-values noted for statistical significance.*

FDA Label Image

Figure5 (Trospium Fig5)

Line graph depicting the mean change from baseline in urge incontinence episodes per week over 12 weeks of treatment. The graph compares placebo (325 participants) represented by a dashed line with open circles, and SANCTURA® (323 participants) represented by a solid line with filled circles, showing greater reduction in urge incontinence for SANCTURA® throughout the study with statistical significance noted at weeks 1, 4, and 12.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.